Products - Arthritis | Topic | NICE

Showing 82 products

Date | Title

Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) (TA982)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2024
GaitSmart rehabilitation exercise programme for gait and mobility issues (MTG78)
Product type:
Guidance
Programme:
Medical technologies guidance
Published:
3 April 2024
Tofacitinib for treating active ankylosing spondylitis (TA920)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 October 2023
Bimekizumab for treating axial spondyloarthritis (TA918)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 October 2023
Bimekizumab for treating active psoriatic arthritis (TA916)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 October 2023
Radiofrequency denervation for osteoarthritic knee pain (IPG767)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 June 2023
AposHealth for knee osteoarthritis (MTG76)
Product type:
Guidance
Programme:
Medical technologies guidance
Published:
11 April 2023
Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2023
Osteoarthritis in over 16s: diagnosis and management (NG226)
Product type:
Guidance
Programme:
NICE guideline
Published:
19 October 2022
Upadacitinib for treating active ankylosing spondylitis (TA829)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 September 2022
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 September 2022
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 August 2022
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 July 2022
Gout: diagnosis and management (NG219)
Product type:
Guidance
Programme:
NICE guideline
Published:
9 June 2022
Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) (IPG727)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
1 June 2022
Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis (IPG726)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 May 2022
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Upadacitinib for treating moderate rheumatoid arthritis (TA744)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 November 2021
Genicular artery embolisation for pain from knee osteoarthritis (IPG708)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 October 2021
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 October 2021
Lateral elbow resurfacing for arthritis (IPG705)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 September 2021
Magnetic resonance therapy for knee osteoarthritis (IPG702)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 August 2021
Ixekizumab for treating axial spondyloarthritis (TA718)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 July 2021
Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 July 2021
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 July 2021
Anakinra for treating Still’s disease (TA685)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 March 2021
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 February 2021
Upadacitinib for treating severe rheumatoid arthritis (TA665)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 December 2020
Rheumatoid arthritis in adults: management (NG100)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
12 October 2020
Published:
11 July 2018
Midcarpal hemiarthroplasty for wrist arthritis (IPG663)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 October 2019
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
10 July 2019
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 March 2019
Platelet-rich plasma injections for knee osteoarthritis (IPG637)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 January 2019
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 October 2018
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 August 2018
Golimumab for treating non-radiographic axial spondyloarthritis (TA497)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 January 2018
Total distal radioulnar joint replacement for symptomatic joint instability or arthritis (IPG595)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
8 November 2017
Sarilumab for moderate to severe rheumatoid arthritis (TA485)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 November 2017
Tofacitinib for moderate to severe rheumatoid arthritis (TA480)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 October 2017
Baricitinib for moderate to severe rheumatoid arthritis (TA466)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 August 2017
Spondyloarthritis in over 16s: diagnosis and management (NG65)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 June 2017
Published:
28 February 2017
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 May 2017
Ustekinumab for treating active psoriatic arthritis (TA340)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
3 March 2017
Published:
4 June 2015
Apremilast for treating active psoriatic arthritis (TA433)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 February 2017
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 October 2016
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2016
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 January 2016
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2015
Joint distraction for ankle osteoarthritis (IPG538)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
16 December 2015
Joint distraction for knee osteoarthritis without alignment correction (IPG529)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 July 2015
Implantation of a shock or load absorber for mild to moderate symptomatic medial knee osteoarthritis (IPG512)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 January 2015
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 February 2014
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 November 2013
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 February 2012
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2011
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2011
Golimumab for the treatment of psoriatic arthritis (TA220)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2011
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 August 2010
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 August 2010
Shoulder resurfacing arthroplasty (IPG354)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 July 2010
Individually magnetic resonance imaging-designed unicompartmental interpositional implant insertion for osteoarthritis of the knee (IPG317)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 September 2009
Total wrist replacement (IPG271)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 August 2008
Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis (IPG230)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 August 2007
Metatarsophalangeal joint replacement of the hallux (IPG140)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 November 2005
Artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis (IPG110)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 February 2005
Artificial trapeziometacarpal joint replacement for end-stage osteoarthritis (IPG111)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 February 2005
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Product type:
Advice
Programme:
Evidence summary
Published:
21 July 2020
FLEXISEQ for osteoarthritis (MIB80)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
14 September 2016
Osteoarthritis in over 16s (QS87)
Product type:
Quality standard
Last updated:
19 October 2022
Published:
11 June 2015
Rheumatoid arthritis in over 16s (QS33)
Product type:
Quality standard
Last updated:
9 January 2020
Published:
28 June 2013
Spondyloarthritis (QS170)
Product type:
Quality standard
Published:
28 June 2018
Sternoclavicular joint replacement for arthritis
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Total hip arthroplasty using the superpath approach for osteoarthritis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Insertion of a synthetic cartilage for first CMC osteoarthritis
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Bimekizumab for treating ankylosing spondylitis TS ID 10334
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 TS ID 11848
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Arthrosamid for symptomatic treatment of knee osteoarthritis
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
Deucravacitinib for treating active psoriatic arthritis TS ID 11981
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Radiofrequency denervation for OA shoulder pain
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Digital platforms for community based self-management of mild to moderate osteoarthritis and joint pain: Early value assessment
Status:
Awaiting development
Programme:
Health technology evaluation
Expected publication date:
TBC